Piramal Pharma Limited Reports FY26 Financial Results

Piramal Pharma Limited has announced its financial results for the fourth quarter and full year ending March 31, 2026. The company reported a slight YoY decline in revenue for FY26, attributed to factors such as inventory destocking and slower order inflows. Consolidated revenue for the year stood at ₹8,869 crore, a 3% decrease from FY25.

The CDMO segment saw a 10% decline in revenue, while CHG and PCH segments experienced growth of 3% and 17% respectively. EBITDA margins decreased from 17% to 13% over the year. Despite these challenges, Piramal focused on cost optimization and operational excellence, which partly offset lower revenues.

Nandini Piramal highlighted the recovery in biopharma funding and the positive impact of the Kenalog® acquisition. The company expects growth in all segments in FY27, driven by these strategic moves. Capital expenditure totaled US$94 million, with expansions at Lexington and Riverview advancing well.